The DDMoRe Foundation was founded in April 2016 with the aim to maintain and enhance the published open-source DDMoRe standards and tools to deliver and improve the quality, efficiency and cost effectiveness of Model-Informed Drug Discovery & Development (MID3) and Therapeutic Use. Its current partners consist of Pharmaceutical Companies and Academic Institutions that drive the strong belief that Model-Informed Drug Discovery and Development will profit from standardisation and integration. By elaborating on principles like model sharing and interoperability based on standards, the foundation will support the community with knowledge and integrated tools to improve efficiency in model building.
Drug development decision makers rely on robust rationale to select drug candidates, targets, trial designs, dose regimens, patient populations and suitable endpoints. A lack of knowledge integration to support informed decision making has detrimental effects on patients, discovery and development program choices, and will incur significant financial inefficiencies. Model-Informed Drug Discovery and Development (MID3) provides a quantitative basis for informed risk assessments. MID3 including quantitative systems pharmacology approaches is essential to perform knowledge integration.
The DDMoRe Foundation will provide a variety of Foundation Partner specific benefits and be a catalyst for further developments and enhancements in this quantitative arena that service the needs of a broader Global Foundation Partnership as a whole. The foundation is open towards any interested party; including organizations which were, or were not, part of the IMI DDMoRe consortium during its lifetime.